The goal of this intervention clinical trial is to learn about the protection of isomaltooligosaccharides (IMO) on intestinal bacterial translocation in patients with liver cirrhosis. The main question is to answer the changes of LPS after adminstration of IMO.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
18
Patients will still receive standard treatment, including medicine and other invasive treatment.
Nanfang Hospital
Guangzhou, Guangdong, China
RECRUITINGChanges of Lipopolysaccharide (LPS) in plasma
LPS will be tested by Tachypiens Amebocyte Lysate (TAL) test
Time frame: Before (Day-0) and after treatment (Day-8).
Changes of bacterial load in plasma
Count the Colony-Forming Units (CFU) to value the bacterial load
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of infections (CRP) in plasma
C-reactive protein
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of infections (PCT) in plasma
Procalcitonin，PCT
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of kidney failure (Cr) in plasma
Creatinine，Cr
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of coagulation failure (INR) in plasma
International normalized ratio，INR
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of markers of liver failure (TBIL) in plasma
Total bilirubin，TBIL
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
Changes of Lipopolysaccharide (LPS) in plasma after 7-day non-treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
LPS will be tested by Tachypiens Amebocyte Lysate (TAL) test
Time frame: After 7-day non-treatment (day 15).
Incidence of bacterial infection
All kinds of infection, including pneumonia, SBP, urine tract infection and so on.
Time frame: After treatment (Day-8) up to follow-up (Day-28)
Development of acute-on-chronic liver failure
Diagnosis of ACLF is based on the criteria of EASL-ACLF.
Time frame: After treatment (Day-8) up to follow-up (Day-28)
Changes of Meld scores which evaluate severity of liver diseases.
Model for End-Stage Liver Disease (MELD) is used to estimates a patient's chances of surviving their disease during the next three months. This numerical scale is used for adult patients waiting for a transplant. The MELD score ranges from 6 to 40 (gravely ill). The individual score tells you what is the urgency of undergoing a liver transplant during the next 90 days (three months).
Time frame: Before (Day-0) ,after treatment (Day-8), after 7-day non-treatment (day 15).
28-day mortality
Time frame: Day-28